In a prospective single-arm phase II (VISION) study, tepotinib had an objective response rate (ORR) of 46% and a median duration of response (DoR) of 11.1 months in NSCLC patients with MET exon 14 skipping mutation [13], which was approved by the Pharmaceuticals and Medical Devices Agency of Japan on March 25, 2020. Here, MET is linked to non-small cell lung carcinoma.